BAL PHARMA LTD. - 524824 - Announcement under Regulation 30 (LODR)-Newspaper Publication
We are submitting to the exchange newspaper advertisements of Notice issued to our shareholders on 26.07.2023 regarding transfer of equity shares to the IEPF a/c and published in Financial Express ( English ) and Sanjay Vani ( Kannada) , on 31.07.2023. BAL PHARMA LTD. - 524824 - Notice To The Shareholders Reg Transfer Of Shares To IEPF A/C
We have circulated the enclosed Notice to all our shareholders whose shares are liable to be transferred to IEPF a/c, for the financial year 2023.24. List of shareholders whose shares are eligible for transfer to IEPF a/c as they have not encased their dividend for the last seven consecutive years , is also uploaded on our website. BAL PHARMA LTD. - 524824 - Initial Disclosure -Large Corporate-Revised
Pursuant to SEBI Circular No.SEBI/HO/DDHS/P/CIR/2021/613 dated 10th August 2021, we hereby confirm that Bal Pharma Limited is not a large corporate for the financial year 2023-2024. BAL PHARMA LTD. - 524824 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
We are submitting to the exchange intimation received from our R&T agents regarding loss of share certificate by one of our shareholder. BAL PHARMA LTD. - 524824 - Announcement under Regulation 30 (LODR)-Newspaper Publication
We are submitting to the exchange, news paper advertisements of the Notice of the Postal ballot issued to our shareholders on 20.07.2023 and published in Financial Express ( English) and Sanjayvani ( Kannada ) newspapers on 21.07.2023 BAL PHARMA LTD. - 524824 - Shareholder Meeting / Postal Ballot-Notice of Postal Ballot
We are submitting to the exchange copy of the Postal Ballot Notice that is being circulated among the shareholders of the Company seeking their approval for Appointment of Ms.Nicola Neeladri ( DIN # 01997936 ) as Independent Director of the Company by a special resolution. BAL PHARMA LTD. - 524824 - Appointment of Company Secretary and Compliance Officer
As per the provisions of Section 203 of the Companies Act,2013, the Board of Directors of the Company at their meeting held on 17.07.2023 has appointed Mr.Abdul Basith ( Membership # A70640) as Company Secretary and Compliance Officer of the Company. BAL PHARMA LTD. - 524824 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Based on the certificate received from our R&T agents i.e TSR Darashaw Pvt Ltd, we would like to confirm that the details of securities dematerialized /rematerialized during the quarter ended 30.06.2023 have been furnished to all the stock exchanges where the equity shares of the Company are listed , within the prescribed time limit. The share certificates received for dematerialization , if any have been mutilated and cancelled after due verification and the name of the depository has been substituted in the records as registered owner , within 15 days of the receipt of the certificate of security. BAL PHARMA LTD. - 524824 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
We are submitting to the exchange intimation received from our R&T agents i.e TSR Consultants Pvt Ltd , Mumbai regarding issue of duplicate share certificate in lieu of lost/misplaced original share certificate to one of our shareholder. Please take the intimation on record. BAL PHARMA LTD. - 524824 - Closure of Trading Window
Pursuant to the Code of Conduct of the Company and as per the amended provisions of SEBI(Prohibition of Insider Trading ) Regulations, We wish to inform the exchanges that the trading window for dealing with the securities of the Company on designated employees and their relatives will be closed from 1st July 2023 and up to 48 hours of the declaration of the Un-Audited financial results of the Company for the quarter ended 30.06.2023. The date of the Board meeting for declaration of the Un-Audited financial results will be intimated to the exchanges in due course.